Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging

Fineline Cube Feb 6, 2026
Company Deals

Knature Biopharmaceutical Files Hong Kong IPO to Advance Mitochondrial Medicine and NAD+ Therapeutics

Fineline Cube Feb 6, 2026
Company Deals Digital

XtalPi Partners with Visen Pharma to Accelerate AI‑Driven Endocrine Drug Discovery

Fineline Cube Feb 6, 2026
Company Deals

Shanghai Pharma to Divest 30% Stake in Sino-American Squibb for $147M

Fineline Cube Feb 6, 2026
Company Deals

Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal

Fineline Cube Feb 5, 2026
Policy / Regulatory

China’s NHSA Opens NRDL to AI and Digital Health Innovation, Unveils Scenario‑Driven Reimbursement Reform

Fineline Cube Feb 6, 2026
Company Drug

Fosun Pharma’s Fumaining Wins Priority Review for NF1 Adult Indication in China

Fineline Cube Feb 6, 2026
Company Drug

Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial

Fineline Cube Feb 6, 2026
Company Drug

Clover Biopharmaceuticals Administers First Dose of COVID-19 Vaccine SCB-2019 in Zhejiang

Fineline Cube Feb 14, 2023

China-based Clover Biopharmaceuticals, Ltd (HKG: 2197) has announced the first jab of its COVID-19 vaccine...

Company Deals

Hengrui Pharmaceuticals Licenses SHR2554 to Treeline Biosciences

Fineline Cube Feb 13, 2023

China’s Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced a licensing agreement with US-based Treeline Biosciences,...

Company Deals Drug

CSPC Pharmaceutical Licenses ADC SYS6002 to Corbus Pharmaceuticals

Fineline Cube Feb 13, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced a licensing agreement with Massachusetts-based Corbus...

Company Deals

Mingche Biotechnology Secures Pre-Series A Funding for Medical Device Innovation

Fineline Cube Feb 13, 2023

China-based high-value medical device firm Mingche Biotechnology (Suzhou) Co., Ltd has reportedly raised “tens of...

Company Deals

Dessight Biomedical Secures Pre-Series A Funding for Ophthalmic Innovations

Fineline Cube Feb 13, 2023

Hangzhou Dessight Biomedical has reportedly raised “tens of millions” of renminbi in a Pre-Series A...

Company Drug

Luye Pharma Initiates Phase I Study for BA1106, a CD25 Monoclonal Antibody

Fineline Cube Feb 13, 2023

China-based Luye Pharma Group (HKG: 2186) has announced the first subject dosing in a Phase...

Company Drug

Zelgen’s ZGGS15 Accepted for NMPA Review as First Global BsAb Filing

Fineline Cube Feb 13, 2023

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that a clinical trial filing for...

Company Drug

Kintor’s GT20029 Shows Positive Results in US Phase I Study for AGA and Acne

Fineline Cube Feb 13, 2023

China-based Kintor Pharmaceutical Ltd (HKG: 9939) has announced positive topline data from a Phase I...

Company Drug

Hengrui’s HER2-Targeted ADC SHR-A1811 Aims for Breakthrough Designation

Fineline Cube Feb 13, 2023

China’s Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced that its SHR-A1811, an HER2 targeted antibody-drug...

Company Drug

EOC Pharma’s CDK7 Inhibitor EOC237 Accepted for CDE Review

Fineline Cube Feb 13, 2023

EOC Pharma, a biotech operating out of the US and China, has announced that a...

Company Drug

Joincare’s Generic Seretide Accepted for NMPA Review

Fineline Cube Feb 10, 2023

China-based Joincare Pharmaceutical Industry Group Co., Ltd (SHA: 600380) has announced that the market filing...

Company Deals

Nona Biosciences Partners with Mythic Therapeutics for Next-Gen ADCs

Fineline Cube Feb 10, 2023

Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), has struck a partnership...

Company Drug

Everest Medicines’ Nefecon Included in South Korea’s GIFT Program

Fineline Cube Feb 10, 2023

China-based Everest Medicines (HKG: 1952) has announced that South Korea’s Ministry of Food and Drug...

Company Deals

Haohai Bio Acquires Additional Stake in SZNIMO for Ophthalmic Expansion

Fineline Cube Feb 10, 2023

China-based Shanghai Haohai Biological Technology Co. Ltd (HKG: 6826, SHA: 688366), a leading biomaterial firm...

Company Drug

Hinova’s HP530S Accepted for NMPA Review as FAK Inhibitor for Solid Tumors

Fineline Cube Feb 10, 2023

China-based biopharma Hinova Pharmaceuticals (SHA: 688302) has announced that a clinical trial filing for its...

Company

AstraZeneca Reports Q4 and Full-Year 2022 Results with Strong Revenue Growth

Fineline Cube Feb 10, 2023

UK-based multinational AstraZeneca Plc (AZ, NASDAQ: AZN) has released its financial results for the Q4...

Company Drug

Qilu Pharmaceutical’s QLS12004 Gains Tacit Clinical Trial Approval

Fineline Cube Feb 9, 2023

The Center for Drug Evaluation (CDE) website indicates that China-based Qilu Pharmaceutical’s Category 1 chemical...

Company Deals

Sino Biopharmaceutical Terminates IPO Pre-Listing Process for STAR Board

Fineline Cube Feb 9, 2023

Sino Biopharmaceutical Ltd (HKG: 1177) has announced the decision to terminate the pre-listing process for...

Company Deals

Shanghai Pinnacles Partners with Sysmex for Biochemical Immune Diagnosis Solutions

Fineline Cube Feb 9, 2023

China’s Shanghai Pinnacles Medical Technology Co., Ltd has struck a partnership with Japan-based Sysmex Corporation,...

Company Deals

GenScript ProBio Partners with Bio Immunitas for hRPP Platform

Fineline Cube Feb 9, 2023

Nanjing-based GenScript ProBio, a leading biologics Contract Development and Manufacturing Organization (CDMO), has formed a...

Posts pagination

1 … 519 520 521 … 621

Recent updates

  • Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging
  • Fosun Pharma’s Fumaining Wins Priority Review for NF1 Adult Indication in China
  • Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial
  • Akeso’s Ivonescimab Secures Fifth Breakthrough Therapy Designation for Biliary Tract Cancer in China
  • Ascentage Pharma Secures NMPA Approval for APG‑3288 BTK Degrader Trial in Hematologic Malignancies
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging

Company Drug

Fosun Pharma’s Fumaining Wins Priority Review for NF1 Adult Indication in China

Company Drug

Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial

Company Drug

Akeso’s Ivonescimab Secures Fifth Breakthrough Therapy Designation for Biliary Tract Cancer in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.